University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Student Research Projects, Dissertations, and
Theses - Chemistry Department

Chemistry, Department of

5-2011

PURIFICATION OF LYSINE DECARBOXYLASE: A MODEL SYSTEM
FOR PLP ENZYME INHIBITOR DEVELOPMENT AND STUDY
Leah C. Zohner
University of Nebraska-Lincoln, leahcthompson@huskers.unl.edu

Follow this and additional works at: https://digitalcommons.unl.edu/chemistrydiss
Part of the Chemistry Commons

Zohner, Leah C., "PURIFICATION OF LYSINE DECARBOXYLASE: A MODEL SYSTEM FOR PLP ENZYME
INHIBITOR DEVELOPMENT AND STUDY" (2011). Student Research Projects, Dissertations, and Theses Chemistry Department. 21.
https://digitalcommons.unl.edu/chemistrydiss/21

This Article is brought to you for free and open access by the Chemistry, Department of at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Student Research Projects,
Dissertations, and Theses - Chemistry Department by an authorized administrator of DigitalCommons@University of
Nebraska - Lincoln.

PURIFICATION OF LYSINE DECARBOXYLASE: A MODEL SYSTEM FOR PLP
ENZYME INHIBITOR DEVELOPMENT AND STUDY

By

Leah Zohner

A THESIS

Presented to the Faculty of
The Graduate College at the University of Nebraska
In Partial Fulfillment of Requirements
For the Degree of Master of Science

Major: Chemistry

Under the Supervision of Professor David B. Berkowitz

Lincoln, Nebraska

May, 2011

PURIFICATION OF LYSINE DECARBOXYLASE: A MODEL SYSTEM FOR PLP
ENZYME INHIBITOR DEVELOPMENT AND STUDY
Leah Zohner, M.S.
University of Nebraska, 2011
Advisor: David Berkowitz
Pyridoxal phosphate (PLP) dependent enzymes have the ability to manipulate amino acid
substrates, serving variously as (i) racemases, transaminases, and beta- or gamma eliminases (all
involving Cα-H bond cleavage); (ii) decarboxylases (Cα-CO2- bond cleavage), or (iii)
retroaldolases (Cα-Cβ bond cleavage). Dunathan posited that stereoelectronics govern the key
C-X bond cleavage step across the class of PLP enzymes; namely by aligning the scissile bond of
the substrate with the extended pi system of the substrate-PLP imine that bond is weakened. A
mechanistic understanding of electron flow in this enzymatic class has motivated many groups,
including the Berkowitz group, to develop mechanism-based enzyme inactivators for specific
PLP enzymes. Most relevant to this thesis is the finding that L-alpha-(2’Z- fluoro)vinyllysine,
designed as a “suicide substrate” is, indeed, an efficient irreversible inactivator (t1/2 ~ 3 min, Ki
~ 100 uM, partition ratio ~ 16) of lysine decarboxylase from Hafnia alvei (K. R Karukurichi et
al. J. Am. Chem. Soc. 2007, 129, 258-9) while the D-antipode is a slow substrate.
This thesis is motivated by the desire to better understand this interesting result at the
molecular level. Described is a streamlined protocol for the purification of this useful model
enzyme from the native source, Hafnia alvei.. The ultimate goal is prepare homogeneous protein
of sufficient quality and quantity to permit its successful crystallization to yield diffraction
quality crystals. This thesis details and documents an improved purification procedure of LDC,

as well as presents preliminary data toward its crystallization. The thesis will also review related
key precedents in the field, both for the successful mechanism based inactivation of PLPdependent enzymes, and for the structural inactivation, principally involving with protein
crystallography
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I. Background

a) Pyridoxal Phosphate
Pyridoxal phosphate (PLP) is the
active form of Vitamin B61. PLP serves as
an essential cofactor for a variety of
enzymatic processes.2 The beauty of PLP is
its ability to serve a variety of functions.
Figure 1.1 Vitamin B6 and PLP

PLP-dependent enzymes generally perform

chemistry on amino acids, and can cleave bonds to the α-carbon in transamination,
racemization, decarboxylation, and retroaldolase reactions.1-3 At the β- and γ-positions,
PLP enzymes have the ability to facilitate eliminations or replacements.3
Harmon Dunathan (Haverford College) proposed a now classic model to explain
how PLP-dependent enzymes are able to use a single cofactor for so many
transformations, and yet maintain specificity for a particular reaction within a given
active site.4 He proposed that a given PLPenzyme active site is able to dictate which
bond to the α-carbon is broken by aligning
that C-X bond with the extended pi-system
of the cofactor imine. The Dunathan
hypothesis implies that the ensuing
electron delocalization is able to lower the
energy of the transition state for bond

Figure 1.2 The Dunathan Hypothesis
(illustrated for a decarboxylase active site)
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breaking, thereby increasing the rate of the reaction. This stereoelectronic argument has
found general acceptance among PLP chemists, although there is some discussion on the
generality of the concept.4-6 Both computational7,8 and kinetic9,10 studies are also
consistent with the Dunathan hypothesis. Figure 1.2 depicts a Cα-CO2- bond aligned with
the pi-system, as expected for a decarboxylase enzyme. By rotating around the Cα-N
bond in 120° intervals, one arrives at the predicted transition state geometries for a
racemase (Cα-H bond aligned), or a retroaldolase (Cα-Cβ bond aligned).
The Dunathan hypothesis is discussed as it proposes that there are certain
electronic and geometric constraints upon PLP catalysis, and elements of this hypothesis
are testable by x-ray crystallographic examination of PLP enzymes. This thesis is
concerned with the purification of lysine decarboxylase, toward its eventual
crystallization, by those who will continue on the project. As will be discussed below,
identification of an active site proton donor in the vicinity of the cofactor’s pyridine
nitrogen is a key element in considering the likelihood of complete electron
delocalization (i.e formation of a quinonoid intermediate) along the PLP enzyme reaction
coordinate. Solution of the three dimensional structures of either an internal aldimine or
(better) an external
aldimine (e.g. with
a bound substrate
analogue or
inhibitor) allows
one to better
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identify such active site residues.
On the other hand, the fact that nature has also evolved pyruvamide dependent
enzymes that are able to catalyze some of the same reactions as PLP-dependent enzymes
suggests that extended electronic delocalization is not always essential for such

chemistry. For example, bacterial histidine decarboxylase converts L-histidine to
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histamine by utilizing PLP (Gram-negative species) or pyruvamide (Gram-positive
species)11 For a pyruvamide enzyme, the presumed intermediate upon decarboxylation,
would delocalize the resultant electron density across three centers and four p-orbitals, as
opposed to 5 centers and 9 p-orbitals for a fully delocalized PLP-based system. Table
1.111-19 depicts a variety of PLP- and pyruvamide-dependent histidine decarboxylases,
along with their kinetic constants. By analyzing other PLP-only-dependent amino acid
DC’s, it is seen that kinetic data for histidine DC are not atypical for such enzymes.
Specifically, aromatic amino acid DC displays kcat values of 188, 122 and112, as
compared with 52, 92, 107,0.9 and101 for the PLP-dependent histidine DC. For arginine
DC, the difference between the PLP-dependent (kcat =18.5 and 704 ) and pyruvamidedependent (kcat = 2.65 ) enzymes is larger suggesting that, perhaps as much as an order
of magnitude in rate
enhancement may be
gained via the increased
conjugation in PLP vs.
pyruvamide 20 Other
kinetic data from other
PLP-dependent
AADC’s such as
ornithine
decarboxylase21,22 and
lysine decarboxylase23
Figure 1.4 WT alanine racemase with alanine phosphonate

supports this theory,
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seeing kcat values ranging from 3.1 to 383 sec-1. Interestingly, overall it appears that there
is not a large nor a general correlation between catalytic efficiency and cofactor used
across the family of AADC enzymes. This observation increases interest in studying the
validity and generality of the both the bond alignment and the pi-delocalization tenets of
the Dunathan hypothesis.
Another enzyme that has been widely studied in debate over the Dunathan
hypothesis is alanine racemase. According to the crystal structure of alanine racemase,
there are three essential residues that give insight to the mechanism. In the conversion of
L-alanine to D-alanine, tyrosine-265 serves as the essential base to deprotonate the αproton on the si-face of bound L-alanine. This is inferred from the crystal structure of a
bond phosphono-analogue of L-alanine (pdb 1BD0). Reprotonation by the active site
lysine (Lys 39) residue then likely occurs on the re-face, allowing for conversion of Lalanine to D-alanine (Figure 1.5).
Toney uses this crystal structure to argue that even in the absence of a quinonoid
intermediate, a PLP-enzyme is still able to catalyze a racemase reaction at good rates.
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His argument is based on the presence of arginine-219 near the pyridine nitrogen. Given
the generally lower acidity of a guanidium functionality (pKa ~ 12.5 for free Arg)
compared to a carboxylic acid functionality (pKa~ 3-5 in solution), Toney hypothesizes
that the formation of a quinonoid intermediate is less likely in this enzyme. Inspecting
this structure, I find that the pyridine-N/Arg-219-N distance is measured at 2.93 Å, in
contrast to 2.6 Å, for the aspartate oxygen-pyridine nitrogen in the crystal structure of
ornithine decarboxylase from Lactobacillus (pdb ID 1ORD), hinting that hydrogen
bonding is still present but there may not be a complete transfer of the proton. Toney
utilizes a pKa argument, stating that in solution the arginine has a pKa of 12.6 is unlikely
to protonate the nitrogen within the pyridine ring with a pKa of 5. It is well to note that
active site bases can have dramatically lowered pKa’s in appropriate active sites.
Perhaps the classic case here is that the active site lysine in acetoacetate decarboxylase,
estimated by Westheimer and co-workers to be 5.9, based upon active site titration of 2,4dinitrophenyl propionate with acetoacetate decarboxylase. 24
These initial results gave insight to study the mechanism of alanine racemase.25-28
Toney mutated the active site arginine to a variety of amino acids to study the effect on
reaction rates.26 As Table 1.2 depicts, the weaker proton donors have large affects on the
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rate of reaction, decreasing the catalytic efficiency of the enzyme. On the other hand, one
actually observes the quinonoid intermediate for the R219E by UV analysis. Moreover,
the R219E mutant had an increased propensity to give transamination. WT alanine
racemase favors racemization over transamination 106:1, where R219E alanine racemase
favors racemization over transamination 185:1. This suggests that, in general, (Nprotonated) quinonoid intermediates may have a higher propensity for C4’-protonation,
relative to Cα-protonation, than their non-delocalized aza-allylic anion counterparts.
Accordingly, Toney has suggested while this may prove to be an example that disfavors
the production of the quinonoid intermediate, it also suggests that specificity of the
reaction catalyzed may be dependent on formation of the quinonoid intermediate, or lack
thereof.
b) Lysine Decarboxylase
Although the three dimensional structure of lysine decarboxylase (LDC) has yet
to be determined, the structures of numerous PLP-dependent enzymes have been solved
crystallographically. Despite the vast functionality of PLP-dependent enzymes, all of
these can be categorized into one of five fold types29: aspartate amino transferase family
(Fold Type I), tryptophan synthase family (Fold Type II), alanine racemase family (Fold
Type III), (D)-alanine aminotransferase family (Fold Type IV), and starch and glycogen
phosphorylases (Fold Type V).29
One of the most interesting of the fold types is Fold Type V, which consists of
only glycogen phosphorylase and maltodextrin phosphorylase. These enzymes are
necessary to break and phosphorylate a glycosyl linkage, with PLP bound to an active
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site lysine.30 Withers, as well as others, have seen that PLP is necessary for the reaction
to proceed, however, there is no Schiff base formation as seen in all other PLP-dependent
mechanisms.
In order to better understand the mechanism of glycogen phosphorylase, Withers
developed a series of PLP analogues.31-33 Three mechanisms for glycogen phosphorylase
have been proposed. The first mechanism proposes that PLP phosphate could attack the
C-1 carbon while an active site histidine could serve as a general acid to protonate the
leaving glycosidic oxygen.31 The second hypothesis is that the phosphate group of the
PLP serves directly as a general acid to protonate the leaving oxygen. Evidence has been
obtained by the Withers group that speaks against the second hypothesis. Namely, this
research group was able to replace the cofactor in glycogen phosphorylase with both the
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phosphonate (pKa(2) ~ 8) and the α,α-difluorinated phosphonate (pKa(2) ~ 5.5)
analogues of PLP. Though these are poorer and better Bronsted acids than the native
PLP-phosphate (pKa(2) ~ 6.5) respectively, only minor changes seen in reaction rate are
seen. This in turn suggests that leaving group protonation by cofactor does not occur, at
least not in the rate determining step.
The third proposed mechanism that has been suggested is that the PLP phosphate
(or phosphonate) group can accept a hydrogen bond with inorganic phosphate (HPO42-)
which can facilitate transfer of this phosphate group to glycogen, resulting in α-glucose1-phosphate, as seen in Scheme 1.1a.31 Studies have shown that PLP functions primarily
as an essential bridge to facilitate transfer of an inorganic phosphate to the sugar through
this hydrogen bond.32
This interaction was seen utilizing the natural pyridoxal phosphate, as well as
seeing a comparable rate with the α-difluorinated phosphonate analogue of PLP.31-33
Interestingly, since the mono-fluorinated phosphonate is also able to facilitate the
phosphorylation of α-glucose-1-phosphate, it may not be essential to assist in formation
of the hydrogen bond. In order to
test this proposed mechanism,
Withers and coworkers synthesized
5’-pyridoxal-1-diphospho-α-Dglucose (Figure 1.5b, α-PLPPG),
and its rate of reconstitution was
compared to the rate of
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reconstitution of 5’-pyridoxal-1-phospho-β-D-glucose (β-PLPG). It was found that the
α-PLPPG analogue had a rate of reconstitution that was one third less of PLP, yet was 38
fold better than β-PLPG .31 This difference in rate shows that the pocket of the holozyme
has space sufficient to hold PLP and an additional phosphate group, though it is unlikely
that an actual pyrosphosphate linkage actually forms along the reaction coordinate.
Also, glycogen phosphorylase was found to catalyze cleavage of the alphaglucosidic linkage to PLPP, thus releasing glucose-centered oxocarbenium ion-like
species that ultimately gives glucose and leaves PLPP covalently bound to the enzyme.
This finding is consistent with glycogen phosphorylase using the PLP as a catalyst by
hydrogen bonding with inorganic phosphate, thereby facilitating its attack upon a similar
cationic glucosyl center. The decrease in rate of reconstitution from the pyrophosphatelinked cofactor-glucose construct suggests that the two are likely unattached. Crystal
structures also are unable to unambiguously confirm/refute this hypothesis, although
continued studies along these lines are needed.32,33 Glycogen phosphorylase is a rare case
where chemistry is created without formation of the Schiff base with the substrate.
Chemistry occurs with PLP remaining in the form of the internal aldimine. PLP enzymes
of the other four fold types, however, appear to perform the three basic functions of
general PLP-dependent enzymes.
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Fold Type I (Aspartate aminotransferase Family) is the most well studied of all
PLP-enzyme fold types based on the number of solved crystal structures, and also
accounts for a majority of the PLP dependent enzymes.29 Members of this fold type are
found to be active as homo-dimers, in general, with subunits comprising a large domain
and a small domain. Out of 18 crystal structures identified for Fold Type I, the position
of the cofactor bound appears to be nearly identical in all cases, with the PLP attached to
a lysine side chain in the large domain.29 The Fold Type I family contains many
enzymes, including those breaking three different bonds to the α-carbon, such as
aminotransferase subclass 1 and 2 (alpha-C-H), tyrosine-phenol lyase (alpha-C-H), serine
hydroxymethyltransferase (alpha-C-C(side chain)), bacterial ornithine decarboxylase
(alpha-C-CO2-), as well as others.29 Because LDC has such a high homology with ODC
from Lactobacillus sp., having 34% sequence identity and 51% sequence homology over

Figure 1.6 PLP Dependent Enzyme Fold Types
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731 amino acids (vide infra), it is inferred that LDC likely exists in the Fold Type I
family.
Schneider had developed a table of crystallized enzymes, but since 2000, over 100
crystal structures of PLP-dependent enzymes (without substrates, inhibitors, or
mutations), so his fold type classification was in need of expansion. Again, the table was
developed by looking at protein folds seen in the crystal. Table 1.3 presents my effort to
establish an up to date version of the Schneider table, taking into account the very
significant body of structural data that has since been deposited in the pdb.
Table 1.3 Fold types of PLP-dependent enzymes

Enzyme

Species

Function

Year
discovered

PDB
Code

Fold Type I
Aspartate Amino Transferase

Dialkylglycine Decarboxylase
Tyrosine Phenol-Lyase

chicken34
E. coli35
Pig36
Saccharomyces
cerevisiae37
Thermus Thermophilus 38
Rhodobater sphaeroides39
Plasmodium
falciparu(unpublished)
mouse40

Aminotransferase
Aminotransferase
Aminotransferase

1982
1994
1997

1AAT
1ARS
1AJR

Aminotransferase
Aminotransferase
Transferase

1998
1998
2010

1YAA
1BJW
3NRA

Transferase
Transferase

2010
2010

3K7Y
3PD6

Pseudomonas cepacia41
Citrobacter freundii42
Erwinia
Herbicola(unpublished)

Decarboxylase
Lyase

1994
1997

1DGD
2TPL

Lyase

2003

1C7G

Ornithine Aminotransferase

Human43

Aminotransferase

1998

1OAT

Aromatic Amino Acid Aminotransferase

Paracoccus denitrificans44

Aminotransferase

1998

1AY4

Ornithine Decarboxylase

L. bacillus45

Decarboxylase

1995

1ORD

Glutamate-1-Semialdehyde Aminomutase

Synechococcus sp.46

Aminotransferase

1997

2GSA

Aromatic Amino Acid Aminotransferase
Tyrosine Aminotransferase

Pyrococcus Horikoshii OT347
E. coli48
Typanosoma Cruzi49
Human(unpublished)
Mouse 50

Aminotransferase
Aminotransferase
Aminotransferase
Transferase
Transferase

2001
1999
1999
2008
2010

1DJU
3TAT
1BW0
3DYD
3PDX
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Phosphoserine Aminotransferase

Bacillus circulans
(unpublished)
E. coli51
Bacillus Alcalophilus52
Yersinia pestic
CO92(unpublished)
Cytophaga Hutchinsonii
(unpublished)

Aminotransferase
Aminotransferase
Aminotransferase

1998
1998
2004

1BT4
1BJM
1W23

Transferase

2011

3QBO

Transferase

2008

3FFR

Cystathionine Beta-Lyase

E. coli53
arabidopsis thaliana54

Lyase
Lyase

1996
2001

1CL1
1IBJ

Cystathionine Gamma-Synthase

Nicotiana tabacum55
E. coli56

Lyase
Lyase

1999
1999

1QGN
1CS1

Serine Hydroxymethyl Transferase

Rabbit57
Human58
B. stearothermophilus59

Transferase
Transferase
Transferase

1999
1999
2002

1CJ0
1BJ4
1KKJ

1999

1B9H

3-amino-5-hydroxybenzoic acid synthase

Amycolatopsis
mediterranei60

Adenosylmethionine-8-amino-7oxonanoate aminotransferase

E. coli (unpublished)

Aminotransferase

2000

1DTY

E. coli 61
Mycobacterium
tuberculosis62
Bacillus subtillis62

Transferase

2000

1QJ5

Transferase
Transferase

2008
2009

3BV0
3DOD

Aminotransferase

2004

1GTX

Aminotransferase

2004

1SF2

Transferase

2007

2EO5

7,8-diaminopelargonic acid synthase

gamma-aminobutyrate aminotransferase

63

pig

64

E. coli
Sulfolobus tokodaii strain 7
(unpublished)

2-amino-3-ketobutyrate CoA ligase

E. coli65

Transferase

2001

1FC4

2-aminoethylphosphate transaminase

Salmonella typhimurium66

Transferase

2002

1M32

3,4-dihydroxyphenyl alanine decarboxylase

Drosophila67

Lyase

2010

3K40

Transferase

2005

1VEF

Thermus thermophilus
hb8(unpublished)
Thermotoga maritime
(unpublished)
Aquifex aeolicus
VF5(unpublished)
E. coli68

Transferase

2007

2ORD

Aminotransferase
Transferase

2007
1999

2EH6
1BS0

Pyrococcus
furiosus(unpublished)
Human(unpublished)

Aminotransferase
Transferase

2004
2009

1XI9
3IHJ

Alliinase

Human69
Nostoc sp.70
Allium Sativum71

Aminotransferase
Aminotransferase
Lyase

2003
2004
2007

1H0C
1VJO
2HOR

Alpha-aminodipate aminotransferase

Thermus thermophilus
hb27 (unpublished)

Transferase

2008

2EGY

alpha-amino-epsilon-caprolactam racemase

Achromobater obae72

Isomerase

2009

3DXV

Acetylornithine aminotransferase

Acyl-CoA Synthase
Alanine Aminotransferase

Alanine Glyoxylate Aminotransferase
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Arginine Decarboxylase
ArnB Transferase

E. coli73
Salmonella typhimurium74

Decarboxylase
Lyase

2009
2002

2VYC
1MDX

Aspartate-Beta-Decarboxylase
CsdB
Cystalysin

Pseudomonas dacunhae75
E. coli76
Treponema denticola77

Decarboxylase
Lyase
Transferase

2009
2000
2000

3FDD
1C0N
1C7N

Cystathionine gamma-Lyase
Cysteine desulfurase
DOPA Decarboxylase

Saccharomyces cerevisiae78
Human79
E. coli80
Pig81

Lyase
Lyase
Lyase
Decarboxylase

2002
2006
2003
2001

1N8P
2NMP
1P3W
1JS6

GDP-4-keto-6-deoxy-D-mannose-3dehydratase

E. coli82

Transferase

2006

2GMS

GDP-perosamine synthase

Caulobacter crescentus
cb1583

Transferase

2008

3BN1

Glutamate Decarboxylase

E. coli84

Decarboxylase

2004

1PM
M

Glutamate oxaloacetate transaminase

Human(unpublished)

Transferase

2009

3II0

Isomerase

2007

2E7U

Isomerase

2007

2EPJ

Thermus thermophilus85

Aminotransferase

2004

1V2D

Bacillus circulans86
Thermus thermophilus
hb887

Transferase

2006

2C7T

Decarboxylase

2005

1WYU

E. coli88
Corynebacterium
glutamicum89

Aminotransferase

2001

1GEW

Transferase

2008

3CQ4

Anopheles Gambiae90
Pseudomonas Fluorescens91
Human92
Aedes Aegypti93

Transferase
Hydrolase
Hydrolase
Aminotransferase

2006
2003
2004
2005

2CH1
1QZ9
1W7L
1YIY

Decarboxylase

2009

2ZY2

Lyase

2000

1ELQ

Glutamate-1-Semialdehyde Aminomutase

Glutamine Aminotransferase
Glutamine-2-deoxy-scyllo-inosose
aminotransferase
Glycine Decarboxylase
Histidinol-phosphate aminotransferase

Hydroxykyrnurenine Transaminase
Kynureninase

Thermus thermophilus
hb8(unpublished)
Aeropyrum
pernix(unpublished)

L-Cysteine Lyase

Pseudomonas sp. atcc
1912194
Synechocystis sp. Pcc
671495

LL-Diaminopimelate aminotransferase

arabidopsis thaliana96

Transferase

2008

3EI5

L-Threonine Aldolase

Pseudomonas putida(not
published)
Citrobacter freundiia97
Thermotoga maritime98

Lyase
Lyase
Lyase

2004
2005
2002

1PG8
1Y4I
1M6S

L-Threonine-O-3-Phosphate Decarboxylase

Salmonella enteric99

Decarboxylase

2002

1LKC

Lysine Aminotransferase

Mycobacterium
tuberculosis100

Transferase

2006

2CIN

L-aspartate beta-decarboxylase

L-methionine alpha-, gamma-lyase
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Methionine Gamma-Lyase

Trichomonas
Vaginalis(unpublished)

Lyase

2001

1E5E

Multiple Substrate Aminotransferase

Thermococcus profundus(to
be published)

Transferase

2005

1WST

N-acetylornithine aminotransferase

Salmonella typhimurium101

Transferase

2008

2PB0

O-Acetyl homoserine sulfhdrylase

Thermus thermophilus
hb8(unpublished)

Transferase

2005

2CTZ

Ornithine delta-aminotransferase

Plasmodium falciparum102

Transferase

2010

3NTJ

Lyase

2010

3NDN

Lyase

2005

1V72

Transferase
Transferase
Transferase
Lyase
Lyase

2007
2008
2006
2001
2010

2FYF
3E 77
2FNI
1JF9
3A9X

Transferase

2007

2JG2

Transferase
Lyase

2009
2006

3A2B
2C44

O-succinylhomoserine sulfhydrylase
Phenylserine Aldolase
Phosphoserine Aminotransferase
PseC aminotransferase
Selenocysteine Lyase

Mycobacterium
tuberculosis(unpublished)
Pseudomonas
putida(unpublished)
Mycobacterium
tuberculosis(unpublished)
Human(unpublished)
Helicobacter pylori 26695103
E. coli104
Rattus norvegicus105

Tryptophanase

Pseudomonas
paucimobilis106
Sphingobacterium
multivorum107
E. coli108

Ureidoglycine-gloxylate aminotransferase

Bacillus
subtillis(unpublished)

Transferase

2010

3ISL

1-aminocyclopropane-1-carboxylate
synthase

Malus x domestica109

Lyase

2000

1B8G

Salmonella typhimurium110
E. coli111
Thermus thermophilus
hb8(unpublished)
Salmonella typhimurium112
Clostridium sticklandii113

Lyase
Lyase

1996
1998

1TTP
1TDJ

Lyase
Lyase
Isomerase

2005
2006
2004

1VE5
2GN0
1XRS

Hydrolase
Lyase
Isomerase
Isomerase
Lyase
Lyase
Synthase

2004
2004
2005
2010
2003
2005
2005

1TYZ
1P5J
1V71
3HMK
1UIM
1VB3
2C2B

Lyase

2006

2D1F

Isomerase
Isomerase

1997
2009

1SFT
3E5P

Isomerase

2005

1XFC

Isomerase

2007

2DY3

Isomerase

2008

2ODO

Serine Palmitoyltransferase

Fold Type II
Tryptophan Synthase
Threonine Deaminase

5,6-aminomutase
1-aminocyclopropane-1-carboxylate
deaminase
Serine Dehydratase
Serine Racemase
Threonine Synthase

Fold Type III
Alanine Racemase

Psuedomonas sp. Acp114
Human114
S. pombe (unpublished)
Rattus norvegicus115
Thermus thermophilus116
E. coli (unpublished)
arabidopsis thaliana117
Mycobacterium
tuberculosis118

Geobacillus
stearothermophilus119
Enterococcus faecalis120
Mycobacterium
tuberculosis121
Corynebacterium
glutamicum(unpublished)
Pseudomonas
Fluorescens(unpublished)
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Oenococcus oeni
(unpublished)
Bacillus Anthracis 122
E. coli123

Isomerase
Isomerase
Isomerase

2008
2008
2008

3CO8
2VD8
2RJG

Ornithine Decarboxylase

Mouse124
Trypanosoma Brucei125
Human126

Decarboxylase
Decarboxylase
Decarboxylase

1999
1999
2007

7ODC
1QU4
2OO0

O-Acetylserine Sulfhydrylase

Salmonella typhimurium127
Thermus thermophilus
hb8(unpublished)
arabidopsis thaliana128
Entamoeba histolytica129
Paramecium bursaria
Chlorella virus130
Campylobacter jejuni131

Lyase

2000

1OAS

Lyase
Transferase
Lyase

2005
2005
2008

1VE1
1Z7W
3BM5

Decarboxylase
Decarboxylase

2007
2010

2NV9
3NZP

Decarboxylase

2008

2QGH

Lyase

2003

1HKV

Human133
Drosophila134
E. coli135
Mycobacterium
tuberculosis136

Lyase
Lyase
Transferase

2001
2010
2005

1JBQ
3PC2
2BHS

Transferase

2008

3DWI

O-phosphoserine sulfhydrylase

Aeropyrum pernix K1137

Transferase

2005

1WKV

D-amino acid aminotransferase

L. bacillus138

Aminotransferase

1995

1DAA

Branched-chain Amino Acid
Aminotransferase

E. coli139

Aminotransferase

2001

1I1K

Lyase

2008

3CEB

Lyase

2008

2ZGI

Arginine Decarboxylase

Diaminopimelate Decarboxylase

Cystathionine Beta-Synthase
Cysteine Synthase

Helicobacter
pylori(unpublished)
Mycobacterium
tuberculosis132

Fold Type IV

4-amino-4-deoxychorismate lyase

haemophilus somnus
129py(unpublished)
Thermus thermophilus
hb8140

Aminodeoxychorismate Lyase

E. coli141

Lyase

2000

1ET0

Glycogen Phosphorylase

Oryctolagus cuniculus142

Phosphorylase

1991

1A8I

Maltodextrin Phosphorylase

E. coli143

Phosphorylase

1997

1AHP

Fold Type V

One of the most interesting data points in the table is that ornithine decarboxylase
is found in both Fold Type I and Fold Type III, depending on whether the prokaryotic
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form (Fold Type I) or the eukaryotic form (Fold Type III) is under review. Another
interesting fact is that certain traits are conserved across different fold types. As
expected, all of the enzymes have the cofactor bound by an internal lysine. Also, the
internal lysine is always found in an alpha-helix. This may help explain the observation
of relatively similar chemistry for a great difference in fold types. By utilizing these
similarities and trends seen in fold types, we could predict the fold type of LDC.
Namely, we would predict Fold Type I for this enzyme, based mostly on the sequence
similarity to bacterial ornithine decarboxylase.
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Enzymes were classified by fold type according to a DALI overlay.144 Overlays were
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done comparing the pdb entry for the enzyme in question to those for established
members of each fold type: Fold Type I (1AAT – aspartate aminotransferase), Fold Type
II (1TTP-tryptophan synthase), Fold Type III (1SFT-alanine racemase), Fold Type IV
enzyme (1DAA-D amino acid transaminase), and Fold Type V enzyme (1A8I –glycogen
phosphorylase). Enzymes were characterized by fold type by choosing the pairing that
gave the highest E value (> 15) and low rmsd score (< 2). An example of a typical case
is provided in Table 1.4 for the classification of tyrosine aminotransferase. Figure 1.7
shows examples of these DALI overlays. This general method allows for
characterization of fold type, and thus will likely help provide a menu of appropriate
reference enzymes to investigators for the construction of homology models.

Figure 1.8 Decarboxylase Subfamilies
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Sandmeier and coworkers separately developed a bioinformatic classification of
amino acid decarboxylases (AADC’s).145 They took sequences of 54 amino acid
decarboxylases and performed a sequence alignment. The sequence alignment found that
there were four decarboxylase families. Essentially, each group is separated by sequence
alignments. Group I contains a single enzyme, glycine decarboxylase. Group II contains
the aromatic AADC’s such as tryptophan DC and tyrosine DC. Group III contains the
prokaryotic forms of ornithine, lysine, and arginine DC, which is interesting, because the

Figure 1.8 Decarboxylase Subfamilies
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last and final group, Group IV, contains the eukaryotic versions of ornithine and arginine
DC.145
One should take note of the correlation between fold type and decarboxylase
group. Groups I, II, and III are all related to Fold Type I, while Group IV is related to the
Fold Type III family.145 As seen in the sequence alignment of LDC to bacterial ODC
(Figure 1.9), the two proteins are highly homologous, with 34% sequence identity and
51% sequence homology from a sequence alignment across approximately 731residues,
using Clustal W, on the two proteins.146 Based on the homology to bacterial ODC, LDC
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from Hafnia alvei can be placed in Group III and, as mentioned, most likely will have a
Fold Type I structure. The work described herein builds toward solving that structure.
Even more importantly, Figure 1.6 shows the importance on the strain of ODC used.
A second sequence alignment, by comparing LDC (top) with human ODC (bottom),
shows the distinct differences in homology of LDC with bacterial ODC and human ODC.
Therefore, based on the high similarities with bacterial ODC, we can continue to make
the prediction that LDC will display a Type I fold.
c) Amino Acid Decarboxylases
An AADC (Amino Acid Decarboxylase) performs the decarboxylation of an
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amino acid to form the respective amine. These enzymes have been found to employ
either PLP or pyruvamide as a cofactor.1,2,147 For some AA substrates, both types of
AADC’s are known. Scheme 1.1, which shows the large spectrum of amino acid targets
that can be decarboxylated, does not even cover the full substrate range that AADC’s
exhibit. For example, 5-hydroxytryptophan DC is also decarboxylated by Aromatic
Amino Acid DC and specific PLP-dependent AADC’s are known for arginine, glycine,
and histidine. Interestingly, both LDC and Diaminopimelate Decarboxylase (DAP DC)
have thus far not been found in mammalian sources.2,132 The latter has obvious
implications from the point of view of antibiotic development.
PLP-dependent decarboxylases are believed to proceed through the same basic
general mechanism: 1) transimination, 2) decarboxylation, 3) α-protonation, and 4) a
second transimination.2 The first transimination step proceeds by the attack of the amino
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acid substrate on the internal aldimine (lysine bound) to form the substrate bound
external aldimine and release the enzymatic lysine. Next, with the carboxyl group
aligned with the conjugated pi system, decarboxylation is favored and carbon dioxide is
released, resulting in formation of a quinonoid intermediate. This highly conjugated
intermediate is then protonated at the Cα position. The final step occurs when the active
site lysine attacks the external product aldimine, thereby releasing the final product and
regenerating the internal aldimine.
d) Inhibition of PLP-dependent decarboxylases
There are many useful applications to inhibiting some PLP-dependent AADC’s.
Two enzymes in particular, Trypanosomal brucei ODC148,149 and (L)-DOPA DC,150
are the target of inhibitors that serve as useful clinical therapeutics. (DL)-α-
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difluoromethylornithine (DFMO) is an irreversible, mechanism-based inhibitor of
ODC from Trypanasoma brucei, the parasite responsible for African sleeping sickness
in humans.151 African sleeping sickness is caused when a human is bitten by an
infected fly. Symptoms begin with a painful swollen lesion, and can worsen with
fever, swelling, anemia, and discomfort. If untreated, the trypanosomal infection can
spread to other organs, spinal cord, and the central nervous system.152 DFMO has been
developed as an intravenously delivered drug. The originally proposed mechanism
(Scheme 1.3) is based on the interactions of the inhibitor with mouse ODC.149
Following decarboxylation, DFMO undergoes fluoride expulsion as opposed to α-
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protonation. Next, an internal cysteine is believed to attack the β-position, via an
extended conjugation addition mechanism, resulting in the release of fluoride.149
Reformation of the internal aldimine leads to a covalent modification of cysteine,
resulting in inactivation. In 1999, this inactivation mechanism was further supported
by a crystal structure of the inhibitor bound to the enzyme.148 The crystal structure
depicted in Figure 1.8 shows the covalently bound adduct.
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The second drug discussed is Carbidopa, a drug used in combination therapy for
the treatment of Parkinson’s disease.150,153 Carbidopa is used in combination with LDOPA to cause a dramatic increase of dopamine levels as needed in the substantia nigra
of the brain for those afflicted with this syndrome. Dopamine, an active therapeutic for
Parkinson’s, cannot cross the blood-brain barrier. Carbidopa limits the decarboxylation of
L-DOPA and allowing it to then cross the blood-brain barrier, where it undergoes
decarboxylation to dopamine in the brain. Unlike DFMO, Carbidopa does not become
covalently attached to the enzyme, but rather forms a tightly bound cofactor hydrazone,
as seen in the crystal structure.154 As such, Carbidopa might be regarded as an affinity
reagent, rather than as a mechanism-based inactivator. These two examples show the
effectiveness of both affinity reagents and irreversible, mechanism-based inhibitors on
PLP-dependent enzymes and, also their potential as valuable clinical therapeutic agents.
These examples have inspired our lab to develop new motifs for the mechanism-based
inactivation of AADC’s.
e) Inactivation using vinyl amino acids
Though well established in Europe,155 Vigabatrin is a relative newcomer to the
United States. Vigabatrin, the γ-vinylated analogue of γ-amino butyric acid (GABA),
reduces GABA transaminase activity. By increasing basal levels of the inhibitory
neurotransmitter, GABA, Vigabatrin mediates against epileptic seizures.156 Because of
the added conjugation from the vinyl substituent, the usual quinonoid intermediate can
undergo protonation at either Cγ- or the C4'- carbon. Whereas the former pathway can
lead to inactivation via Michael addition, the latter might lead to adduction via a Mannich
condensation (“Meztler enamine mechanism”).157 Scheme 1.4 illustrates both possible
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mechanisms. The structure of an inhibited enzyme suggested that inactivation proceeds
via conjugate addition of the active site lysine, following azallylic isomerization, as seen
in molecular detail in the E-I structure. This study gives us insight to the potential
mechanism by which an α-vinyl amino acid might inactivate a decarboxylase enzyme.
Investigations by Silverman and coworkers suggest that fluorinating the inhibitor
slightly modifies the mechanism of inhibition.158 While the same basic routes involving
C4' or Cγ inhibition are still available, the mechanistic possibilities are altered. Instead of
stopping immediately after nucleophilic addition of the active site lysine into the vinyl
group during the C4' protonation step, (2'-fluoro)vinyl-GABA is thought to go one step
further than the non-fluorinated inhibitor by releasing fluoride after the conjugate
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addition. Interestingly, no significant difference was observed in effectiveness of
inhibition between the E or Z fluoro alkene used, although the mechanism of inactivation
was altered, due to the ability for fluoride to be utilized as a leaving group.159 The
Silverman studies on florovinyl inhibitors served as some of the key motivations behind
the design of “quaternary”, α-(2'-fluoro)vinyl AA’s in the Berkowitz lab.160 The
quaternary amino acids are expected to be inert to PLP-enzymes that require αdeprotonation, such as GABA transaminase, but may act as covalent inactivators of

30

AADC enzymes, if decarboxylated in such active sites.
f)

Conclusions
Understanding the mechanism of action of an enzyme permits the design,

synthesis, and evaluation of mechanism-based inhibitors. Based on the generalities of
PLP-dependent enzymes155, a viable new “trigger” for the inhibition of LDC was
developed. This approach was inspired by examples such as DFMO and γ-(2'fluoro)vinyl-GABA, for both of which latent electrophiles are unveiled in the target PLPenzyme active sites, ODC and GABA transaminase, respectively, resulting in inactivation
of these target enzymes.161
After successful synthesis of the L-α-(2'Z-fluoro)vinyllysine (FVL) by
Karukurichi and de la Salud Bea,23,162 inhibition of H. alvei LDC was found to be
irreversible. On the other hand, the D-antipode functioned as a slow substrate. These
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provocative results within a new AADC inactivation
motif motivated the research described in this M.S.
thesis. It became a central goal to obtain high titres (i.e.
multi milligram) of homogeneous H. alvei LDC so that
this model AADC enzyme might be crystallized and its
structure determined for the first time. In principle, this could then lead to the
interrogation of covalent LDC inactivation by X-ray crystallography, as well.
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II. Purification of LDC
a) Previous Purification method
In order to attempt enzyme crystallization, LDC must first be purified. Since
previous attempts to clone LDC from Hafnia Alvei (H. Alvei) have proven ineffective163,
isolation of the native protein was pursued. Attempts at purification of LDC have been
seen164,165, so the process of purification has been built upon a foundation of previous
purification reports.
Bacterial LDC can be found in a variety of strains including: H. alvei, E. coli, and
Vibrio parahaemolyticus. Out of all three bacteria, H. alvei produces the greatest amount
of LDC, compromising 4% of the total soluble protein.164 For this reason, our lab, as
well as others has chosen to isolate LDC from H. alvei. The first published protein
purification of LDC, from Soda and coworkers,164 employed Bacterium cadaveris (also
known as H. alvei - strain IFO 3731), grown up in a controlled medium (L-lysine,
glycerol, peptone, ammonium sulfate, potassium phosphate, magnesium sulfate, and
yeast extract). Cells were broken open by sonication in the presence of protease
inhibitors and PLP. Following a heat treatment step (50 °C), ammonium sulfate cuts
were made, with the first cut having 30% ammonium sulfate saturation and the second
cut with 55% saturation. Once the pellet was re-suspended in buffer, it was loaded on an
ion exchange DEAE-Sephadex column. The fifth step was a phenyl sepharose column,
followed by a second DEAE-Sephadex column. The final step to isolate the protein was
said to be performed by “crystallization,” obtaining small yellow rod-like crystals that
were not tested with an x-ray, with a final purification factor of 61 and a yield of 5.9%,
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with a final specific activity of 86 U/mg. This laborious procedure and modest yield
motivated our lab to seek a streamlined purification procedure.
Berlin and coworkers, the first group to publish a sequence for LDC from H.
alvei, employed a different purification, which also involved size exclusion and an ion
exchange chromatography, and which provided LDC with a supposedly higher specific
activity of 110 U/mg, but the difference may reflect experimental uncertainty or
variation.163,165 The surprising finding in Berlin’s purification was that this specific
activity resulted from a protein that displayed two bands (88 and 66 kDa) on an SDSdenaturing gel.
In our own lab, Karukurichi developed his own purification method for LDC,
which involved sonicating crude cells, a 60% saturated ammonium sulfate precipitation,
phenyl sepharose chromatography, ion exchange (DEAE Sephadex), and finally size
exclusion (S-300) chromatography.23 My research investigated a modified version of this
basic procedure, as described below.

b) Activity Assay
To measure the activity of LDC, de la Salud-Bea and Karukurichi adapted the
previously published Lenhoff assay.23,162 The Lenhoff assay measures the turnover or
lysine to cadavarine by spectroscopically measuring the amount of cadaverine reacting
with picryl sulfonic acid (TNBS).166 The assay works by allowing the enzyme to actively
convert L-lysine to cadaverine in the presence of lysine (8 mM) for a set time. After the
time has passed, enzyme activity is quenched with base and heat. The quenched solution
is then heated (47 °C for 7 minutes). After cooling, TNBS is added to each solution, and
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the reaction is again heated (47 °C for 7 minutes). This allows for nucleophilic aromatic
substitution to occur, covalently attaching cadaverine to the aromatic ring, and
presumable releasing sulfite. Interestingly, lysine in solution will not react with TNBS,
presumably because the amine becomes basic in cadavarine. Lastly, the derivatized
cadaverine is extracted with toluene and its absorbance was measured at 340 nm. The
absorbance measured is then compared to that obtained for a set of standards. For more
information, please refer to the experimental section.

c) Protein determination
From the published sequence of LDC from H. alvei, the molecular weight of LDC
appeared to be 82 kDa (or 82,000 g/mol). Utilizing the Lowry method167, we were able
to compare absorbance against a common standard, Bovine Serum Albumin (BSA),
which has a monomeric molecular weight of 66 kDa. The Lowry method works in two
steps: 1) Reductino of Cu2+ to Cu+1, and 2) Reduction of the Folin reagent.167 The first
step proceeds via a Biuret reaction, where copper is complexed with with amide bonds of
the protein, specifically with aromatic amino acids.167 Potassium hydroxide, CuSO4,
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sodium carbonate, sodium tartrate, and sodium dodecylsulfate are added to the protein
mixture, oxidizing peptide bonds to convert Cu2+ to Cu+.167 The second step involves the
Folin-Ciocalteu reagent being reduced by the copper complex, and the mixtures changes
from a light purple color to a deep blue color, depending on the concentration of protein
in solution, which is measured at 650 nm. A stronger absorbance is related to higher
protein concentration. After setting a calibration curve with BSA weight standards, LDC
protein concentration could easily be estimated.
d) Protein purification
With assays for activity and protein concentration in hand, we next set out to
optimize LDC purification from the native source. Cells were grown in a lysinesupplemented medium (5 g bactopeptone, 5 g yeast extract, 1 g MgSO4•7H2O, 3 g of Llysine monohydrochloride per 1 L of solution), and disrupted via sonication in the
presence of protease inhibitors.

The crude extract was then centrifuged and to the

supernatant was added a 60% ammonium sulfate saturation. Although ammonium sulfate
is generally used in two separate cuts for an increase in purification, preliminary attempts
to improve specific activity in this manner showed little benefit. Instead, the ammonium
sulfate precipitation served as an excellent means for storage, with no activity loss
detected for up to a year or more of storage. This method is a simpler means of storage
as compared to glycerol stocks, because instead of having to use dialysis to remove
glycerol, the resuspended pellet can be immediately loaded onto the next column. The
high ammonium sulfate concentration precipitate insures retention of nearly all LDC
activity in the stored precipitate.
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The first column used was a phenyl sepharose column. Phenyl sepharose is a
hydrophobic stationary phase that separates based on hydrophobicity. Elution was
performed by using a linear gradient from high (100 mM) to low (10mM) concentration
of phosphate buffer (with 15 µM PLP at pH 7.0). By decreasing phosphate
concentration, and hence decreasing ionic strength, one effects the elutions of proteins as
a function of increasing hydrophobicity, with the most hydrophobic eluting last. An
elution plot is shown in Figure 2.1. Fractions displaying high absorbance at 280 nm and
some absorbance at 420 nm were further tested for activity using the Lenhoff Assay, as
described before. The fractions collected in Figure 2.1 led to an purification factor of 2.5
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(seen in Table 2.1a), but in pooling fewer fractions (i.e. two fractions versus the 8 seen in
Figure 2.1) the purification factor was optimized to 12 (Tabel 2.1b), with a yield of
38.9%.. The fractions collected had the highest specific activity as determined by the
Lenhoff and Lowry assays, as described above. Table 2.1b represents the fully optimized
purification table in the purification of lysine decarboxylase.
Active fractions from the phenyl sepharose column were taken on to the next step.
While Karukurichi previously used DEAE-Sephadex as an anion exchange column, this
resin was found to swell dramatically, and yield poor separation.23 Initially, a more basic
quaternary anion exchange column, Q-Sepharose, was used, with very good results in
separation of the protein. This resin showed less dramatic swelling and led to more
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effective protein fractionation. However, the purification achieved via phenyl sepharose
was so significant that it seemed unnecessary to use the Q-sepharose step. Therefore, this
column was eliminated, and the active fractions were loaded onto an S-300 size exclusion
column. This final column simply separates based on size. Larger macromolecules
rapidly traverse the column, while proteins in the size regime of the pores are partially
retained, and elute more slowly. Using this streamlined protocol, homogeneous LDC
was obtained in 13% overall yield with a final specific activity of 91 U/mg. These results
were consistent with previously published data from Karukurichi’s
protein purification.23
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e) The Next Step: Effectiveness of Mass Spectroscopy and Crystallography
Both mass spectrometry and crystallography have been used as effective methods
for the analysis of enzyme sequencing as well as understanding the mechanism of
inhibition of certain enzymes.63,168 In some instances, mass spectrometry has proved
more efficient than crystallization, and vice versa. The methods may be viewed as
complementary. Mass spectrometry has the advantage of allowing one to more easily
examine multiple parallel covalent inactivation mechanisms, because homogeneous
crystals are not needed. Moreover, differential sites of alkylation can be examined a
single “bottom-up” analysis. The price one pays for this is the need to establish
significant sequence coverage, which often requires the use of multiple digestion
enzymes, and which becomes more difficult with larger enzymes. The “bottom-up” MS
method has the disadvantage of likely missing non-covalent inactivation mechanisms
(e.g. Carbidopa) or covalent inactivation mechanisms that can lead to release of inhibitor
upon workup (e.g. Metzler enamine mechanism169,170 – release of the “Schnackerz
intermediate”171,172 under basic conditions.
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Crystallography, on the other hand, is able to give the complete sequence of the
enzyme in its entirety, showing all contributing residues to the active site, without any
digestion. Moreover, non-covalently bound inactivators (e.g. CarbiDOPA) are easily
seen by this method. However, crystallizing a protein can be time consuming in the
attempts to optimize conditions, as well as in learning to growing crystals of a size and
quality to give an acceptable X-ray diffraction pattern. It is worthy to note that this may
soon change with the advent of “free electron laser”-based crystallography. 173,174
Ideally, our lab would try to crystallize LDC to obtain absolute certainty of the
enzyme’s structure, and would then use crystallography or mass spectrometry to identify
the mechanism of inactivation from α-L-(2'-Z-fluoro) vinyllysine on LDC. Studies as
shown by Silverman below help to see the importance of both methods in identifying
mechanisms of inactivation. 168,175
(S)-4-Amino-4,5-dihydro-2-thiophenecarboxylic acid is an effective
inhibitor of GABA-AT.176 Silverman was able to discover a unique means of inhibition
by using electrospray mass spectrometry and tandem mass spectrometry alone to identify
the probable mechanism(s). Out of three mechanisms proposed, all three created
different adducts: 1) an external aldimine that results from aromatization of the product,
2) an enamine type
mechanism, and 3) a Michael
addition. All three create
inactive forms of PLP that will
slowly be removed from
within the active site. If a
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mechanism is proposed and a molecular mass is known, mass spectrometry can help to
validate these proposals. The three candidate structures for the inactive forms of PLP all
vary substantially in molecular weight. Isolating the modified cofactor product and
submitting it to tandem MS/MS allowed for the molecular mass of product 1 to be the
primary candidate, leading their group to conclude that the mechanism of inactivation
proceeds via aromatization of the adduct.
Crystallization offers another means to discovering the path of inactivation. Next
to LDC, ODC from Lactobacillus is the most highly homologous PLP enzyme known to
date. Fortunately, the crystal structure of ODC has been solved by Hackert177; who found
that ODC existed in the crystalline form as a hexamer of dimers, or a total dodecamer.
While the dimer structure seems to fit the fold type 1 of generalized PLP-dependent
enzymes29, the dodecamer is out of the ordinary. It is possible that LDC could crystallize
in a similar manner to ODC based on the high homology, or could behave similarly to
other fold type 1 proteins.
The beauty of crystallography it that is allows for absolute certainty in identity of
each individual amino acid, as well as seeing the identity of the protein as a whole, rather
than in fragments as would be seen in mass spectrometry. This would allow the entire
quarternary structure of LDC to be fully exposed in its entirety. Obtaining a successful
crystal structure would be beneficial in order to have full understanding of the active site,
PLP’s binding, as well as potential inhibitor interactions.

f) Silverman’s Case of Mechanistic Enzymology by Crystallography
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Dr. Richard Silverman has employed isotope labeling, mass spectrometry, and
crystallography in attempts at depicting mechanistic insights to inactivation of
enzymes.175 While all three give insightful hints into the possible mechanism of
inactivation, only crystallization gives scientists a finite structure. Instead of noting
radioactivity in the solution or bound to the enzyme, or instead of being given a mass of a
fragment, an absolute structure is able to be deciphered. In specific cases, this can
finalize the inhibited product, thus giving concrete information regarding mechanism.
Silverman et. al show an extremely useful example to portray the usefulness of
mechanistic crystallography. In the case of GABA-AT, the inhibitor (1R, 3S, 4S)-3amnio-4-fluorocyclopentane was developed based on analogy to the structure of
GABA.168 Studies of activity proved this inhibitor to irreversibly inhibit GABA-AT.
Because GABA-AT is a PLP- dependent enzyme, both Michael addition or Metzler
enamine formation are viable products, as seen in Scheme 3.1. Initially, the mechanism
of GABA-AT was proposed to proceed via Michael addition based on the fact that
aminotransferases begin with C4' protonation being a necessary step, as well as other
inhibitors, like fluoro vinyl GABA proceed via Michael addition, but experiments for this
inhibitor had not been studied. Both mechanisms start in the same fashion. Addition of
the substrate generates the external aldimine, which undergoes deprotonation of the αproton to form the quininoid intermediate, followed by fluoride expulsion. In the
Michael addition, the active site Lys will attack the γ-position of the unsaturated iminium,
which regenerates the quininoid intermediate and results finally in C4' protonation. Via
the Metzler enamine addition, the active site Lys generates the internal aldimine releasing
the small molecule enamine. This enamine is a good nucleophile and is proposed to
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attack the C4' carbon, resulting in the final adduct. Interestingly, both mechanisms result
in fluoride expulsion, thereby eliminating radioactive assays as a means of distinguishing
the two. Similarly, if the Metzler enamine does indeed result of an addition of the small
molecule back into PLP for formation of the final adduct, both mechanisms would give
products of identical molecular weight.
Silverman was not only able to successfully identify the mechanism of
inactivation of GABA-AT, but was able to use crystallography to visualize the active site
and see interacting active site residues.168 Arg 192 is able to stabilize the carboxylic acid
within the inhibitor. Lys 329 serves as the active site lysine that is able to form the
internal aldimine. From these results, Michael addition is conclusively eliminated from a
possible mechanism of inactivation. Formation of the adduct seen gives adequate
information for scientists to hypothesize that the method of inactivation of GABA-AT
proceeds via the Metzler enamine pathway.
g) Possible Inactivation Pathways of LDC with the New Trigger

Based on Silverman’s findings, it was essential that we analyze the
potential paths of inactivation for LDC. PLP-based enzymes proceed through three
major pathways: α- protonation, which results in normal turnover, and two possible
pathways that could result in inactivation: C4' protonation, or Cγ protonation. Another
possible method of inactivation, though highly unlikely, is addition directly into the
quninonoid intermediate. Indeed, careful consideration of the possibilities suggests that
there could be more than one means of inactivation is possible based on C4' protonation,
or Cγ protonation. Because of previous findings within our own lab from Karukurichi
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and de la Salud-Bea, we know that the fluoride expulsion accompanies inactivation.23,162
Of the three most likely inactivation mechanisms, two (nucleophilic Metzler enamine
mechanism and the electrophilic conjugate addition mechanism) follow from Cγ
protonation, followed by enamine formation/release.157,178 The third possible mechanism
was a conjugate addition/elimination following C4' protonation. Scheme 2.3 depicts these
three potential inactivation routes.
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h) Crystallization attempts
Based on Silverman’s findings, our group seeks to obtain a crystal structure of
LDC. This effort is collaborative with Professor Mark Wilson (UNL Biochemistry
Department). Previous attempts by Karukurichi in our lab led to the successful
crystallization of LDC, but the crystals were of insufficient size for diffraction
experiments. Here, preliminary crystallization was performed using 10 mM phosphate
buffer pH 7.0, 15µM PLP, and 15mg/mL LDC, with no positive results. In the second
attempt, the buffer was changed to 10 mM malonate buffer pH 7.0, 15µM PLP, 25
mg/mL LDC, and received two positive hits using the Hampton Screening Kits I and II.
After proper growth conditions were developed (in lab notebook), crystals were
obtained, as pictured in Figure 2.6. This data suggests that crystallization of LDC is
indeed possible.

i)

Conclusions
As results have shown, LDC was successfully purified from the native source, in

moderate to good yields, with acceptable specific activity. Modifications have been
made to the original protocol to eliminate one unnecessary step in purification. From the
original purification as published by Soda with seven total steps, the final purification has
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been reduced to only four steps, with an increased purification factor, initially at 61 and
improved to 79. The more streamlined protocol also provides for an improved yield
(13%) over Soda’s method (5.9%)164
We have a developed a protocol efficient for production of LDC from H. Alvei.
LDC isolation is now streamlined, and future efforts in the group will be directed toward
finding suitable conditions for its effective crystallization. There are numerous benefits
to obtaining a crystal structure. First, a crystal structure would provide the absolute
sequence of the protein, which would be a valuable piece of information. This is
particularly so, given Berlin’s unsuccessful attempts at cloning the enzyme, suggesting a
possible problem with the sequence. The crystal structure would help to resolve several
such outstanding questions about the protein. Next, obtaining a crystal structure would
give us the oligomeric state of LDC in crystalline form. We predict to see a homo-dimer
structure, but it could have some variance, as seen in ODC from L. bacillus.
If the holozyme is able to be crystallized, there is also potential for inhibitors or
substrates to be crystallized as well. Within our own lab, α-D-(2'-Z-fluoro) vinyllysine
was found to be a substrate with slow turnover, so there is a possibility that a crystal
structure could be obtained with the substrate in the active site. This could potentially
provide some insight to the Dunathan hypothesis, if the alignment of the Cα-CO2- is seen
to be aligned with the extended pi system. The second target that was synthesized within
our lab, α-L-(2'-Z-fluoro) vinyllysine, was found to be an irreversible inhibitor of the
enzyme. If we were able to crystallize the inactivated protein with the processed
inhibitor bound, similarly to DFMO in ODC and vinyl-GABA in GABA transaminase,
the crystal structure would give useful insight to the mechanism of inactivation.
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Alternatively, it may be possible to diffuse such a suicide substrate into the crystal of the
holoenzyme, provided that the motion associated with the transamination and inactivation
chemistry would not significantly disrupt the crystals.
Currently, a successful and improved purification has been presented, with
preliminary results showing that crystallization is an obtainable goal. With our lab’s new
purification protocol, crystallization of LDC is within our grasp.
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III. Experimental
Hafnia alvei was grown from a purified sample from K. Karukurichi, which was grown
from Hafnia Alvei strain IFO 3731 was bought from the Institute for Fermentation of
Osaka. Centrifugation was completed using the SorvallRC5B. Protein concentration was
measured using the Lowry assay. Protein activity was measured using the Lenhoff assay.

Purification of Lysine Decarboxylase:
H. Alvei was grown a modified Laemmli broth, consisting of 5 g bactopetpone, 5
g yeast extract, 1g MgSO4•7H2O, and 3 g of L-lysine monohyrdide per 1 L of solution.
Initially, the bacteria was grown in a starter culture consisting of 50 mL of the culture
broth, and after 12 hours at 43 °C was split into six 4 L flasks, containing 2 L of broth.
The solution was kept in a shaker for 3 days at 150 rpm and 43 °C.
To 24 g of wet cells, ethylenediaminetetraacetic acid (EDTA),
phenylmethanesulfonyl fluoride (PMSF), and 80 mL of 10mM potassium phosphate
buffer (Buffer A), and 6 crushed capillary tubes were added to increase surface area, and
separated into two 250 mL beakers. The beakers were sonicated on ice five times in
thirty second intervals, and was centrifuged at 10,000 rpm for 15 minutes. The
supernatant was decanted, and a 500 µL fraction was taken for analysis.
To the remaining liquid, 60% ammonium sulfate saturation was added at 4 °C and
was stirred for 20 minutes until completely dissolved. The mixture was spun at 10,000
rpm for 15 minutes. Nearly all activity (99%) was found in the pellet. The supernatant
was discarded and the pellet was stored at -70 °C.
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The pellet was resuspended in 80 mL of 100 mM potassium phosphate pH 6.0
(Buffer B), and was centrifuged at 15,000 rpm for 15 minutes. The supernatant was
decanted and was concentrated down to 60 mL. The solution was loaded onto a 200 mL
phenyl sepharose column and eluted with a gradiant of 100 mM (250 mL) to 10 mM (250
mL) potassium phosphate buffer, pH 6.0. These fractions were collected in 5.5 mL
increments. To find active protein, 300 µL of each fraction was placed on a 96-well plate
and measured the absorbance at both 280 nm and 420 nm. The fractions were then tested
by the Lenhoff assay, which will be described later.
Active fractions from the phenyl sepharose column were concentrated to 2 mL
and were loaded onto the S-300 column, and was eluted using 10 mM potassium
phosphate buffer with 10 µM PLP, and were collected in 5.5 mL fractions. Active
fractions were measured by the Lenhoff Assay.

Total
Volume

Total

(mL)

Units

Units/mL
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Protein

Specific

(mg)

Activty

Lowry

(U/mg)

%

Purification

Yield

Factor

Assay

Crude

Ammonium
Sulfate

Phenyl
Sepharose

S-300

50

2874

57

2499

1.15

100

1

27

2833

104

2380

1.19

98.6

1.03

4.5

1118

248

81

13.8

62.1

12

1

382

382

4.2

91

13

79

Activity Measurements

Cadavarine Standard
A 2.1 mM solution of cadaverine stock solution was made. 9.5 µL to 95 µL of
the cadaverine solution was added to 24 µL of 100 mM L-lysine. The solution was
finalized to 300 µL by adding 10 mM phosphate buffer, and the tube was heated at 43°C
for 7 minutes. Once brought back to room temperature, 300 µL of 22 mM TNBS was
added and the solution was heated at 43 °C for 7 minutes. Once cooled to room
temperature, 600 µL of toluene was added, and the solution was mixed on a mini vortex 2
times for one minute. 300 µL of the organic layer was extracted and the absorbance was
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measured at 340 nm for a range of concentrations of cadaverine. Absorbance versus
concentration was plotted, and the slope gave the absorbance per 1 µM of cadaverine.

Activity of LDC
Each test tube contained 20 µL of selected LDC and 256 µL of 10 mM phosphate
buffer pH 7.0. At time point 0 minutes, 24 µL of a 100 mM L-lysine solution was added
to the test tube. At the timepoint in which the reaction was desired to be stopped, 300 µL
of 1.0 M K2CO3 was added to quench the reaction, and the mixture was heated at 43 °C
for 7 minutes. After the solution was allowed to cool to room temperature, 300 µL of 22
mM TNBS was added and heated again at 43 °C for 7 minutes. Once the second solution
was cooled to room temperature, 600 µL of toluene was added to the solution. The
mixture was agitated in the mini vortex two times, each lasting for one minute. The final
product resulted in two layers, an orange aqueous layer and a clear to yellow organic
layer. Interestingly, measurements of the crude extract also have a frothy bright yellow
substance at the top of the aqueous layer.
After completing the reaction, a 300 µL aliquot of the toluene layer was placed in
the quartz plate and absorbance was measured at 340 nm. A graph plotting absorbance
vs. time was made, with the slope being used to calculate activity. Based on the
calibration curve, we can calculate the activity units in the 300 µL solution.
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Protein Measurements
For the Lowry Assay, the following solutions can be made ahead of time and used
for multiple assays:
Solution A: 0.5 g CuSO4, 1.0g sodium citrate, and 100 mL dd H2O
Solution B: 20 g Na2CO3, 4g NaOH, and 1L dd H2O
When the assay will be run, the following solutions should be made fresh:
Solution C: 100 mL Reagent B
Solution D: 10 mL Folin-Ciocalteau reagent (SIGMA, 2 N) and 10 mL H2O
The standard protocol was followed:
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1. 10 BSA standards were made in triplicate ranging from 0.1 mg/mL BSA to
1 mg/mL BSA, in increments of 0.1 mg/mL
2. 1.25 mL of solution C and 250 µL of the standard or the protein to be
measured were mixed, vortexed at a medium speed, and were let to sit in an
incubator at 37 °C for 10 minutes.
3. 125 µL of Solution D were added to the solution, vortexed at a medium

speed,

and incubated at 37 °C for 25 minutes.
4. Absorbance of the solutions was measured at 650 nm.
A plot of the standard absorbance versus concentration was made, with the slope of the
plot giving the Abs/mg of protein. The absorbance of the purified protein could also be
used to estimate the amount of protein present in solution.

Ammonium Sulfate Test
A test was run to compare the activity of Karukurichi’s ammonium sulfate
precipitant which had been stored at -80 °C for two years versus a freshly made
ammonium sulfate precipitation. A small fraction of each pellet was re-suspended in 1
mL of 10 mM phosphate buffer pH 7.0 in the presence of 15 µM PLP. 20 µL aliquots
were taken from both samples, and a Lenhoff activity assay was run on the two samples.
Interestingly, the old sample appeared to have slightly higher amounts of activity than the
new pellet, with the activities differing slightly. This shows that even after years of
storage, ammonium sulfate pellets serve as a suitable storage method.
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Native State Determination

Native state determination of LDC was determined by running LDC on a 4% stacking,
9% resolving discontinuous polyacrylamide gel. The gel was run at a constant current of
40 mA and was cooled using flow cooling as set by the Hoeffer Mighty Small II
electrophoresis apparatus. BSA was used as a standard. From the gel, it appears that
LDC exists as a monomer or a dimer, based on molecular weight measurements.
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Sedimentation Equilibrium Experiment
An ultracentrifugation was run to perform a sedimentation equilibrium
experiment. If LDC existed as a dimer, the Beckman-Coullter Proteomelab XLI Protein
Characterization system was run at 8000 rpm with a protein concentration of 0.4 mg mL-1
in a buffer of 10 mM potassium phosphate pH 6.0 at 20 °C for 24 hours, and was run at
11000 rpm under the same conditions to test for a monomer at molecular weight 83 kDa.
Data was collected using Micocal Origin software with the Beckman ultracentrifuge data
analysis add-ons. The data was analyzed at 280 nm. After analysis, and given a 95%
confidence interval, the molecular weight from both runs was shown to be 398 (±22) kDa
based on its sequence. The molecular weight suggests LDC existing in a pentameric
state, which would correlate to work done by Beier, showing a molecular weight of 422
kDa.
An issue regarding these results is that they do not agree with the results obtained
from the gel filtration, however, it may be that LDC is exists as an equilibrium mixture of
several different oligomeric forms. In a simple analysis here, one could have equal
amounts of tetramer and hexamer, giving an apparent averaged molecular weight of a
pentamer.

Crystallization of LDC

1st screening:
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LDC in a 30% glycerol stock was loaded onto a G-25 column and was eluted with 10
mM potassium phosphate buffer pH 6.0 in 10 µM PLP. Fractions were collected
following UV reading at 280 nm, and protein was concentrated down to 5 mg/mL using a
Centricon. Due to the low concentration of protein, trays were set loading 2:1
protein/buffer. Preliminary screening trays were set up utilizing the Hampton I and
Hampton II screening kits. Trays were kept at 9 °C.

2nd screening:
LDC in a 30% glycerol stock was loaded onto a G-25 column and was eluted with 10
mM malonic acid buffer pH 6.0 in 10 µM PLP. Fractions were collected following UC
reading at 280 nm, and protein was concentrated down to 20 mg/mL using a Centricon.
Preliminary optimization trays were performed by utilizing the Hampton I and Hampton
II screening kits. Trays were kept at 9 °C.

Mass Spectroscopy

After collecting S-300 fractions, pure and active fractions of LDC were loaded onto a 9%
SDS PAGE gel. After destaining had occurred, gels were slices and digestion of LDC
was followed by standard protocol (discussed below). The slices were digested with
AspN, formic acid, trypsin, and chymotrypsin. The digested protein was extracted and
run using a C18-reverse phase LC column (75 micron x 15 cm, Pepmap 300, 5 micron
particle size). Results showed multiple hit of various strains of LDC, yet LDC from H.
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Alvei was not the top hit from any of the digestion results. The following depicts
fragments found within the published sequence of LDC from H. Alvei:
Tandem MS/MS for protein modification

Upon sequence alignment, it was seen that the active site lysine exists in a highly
conserved region of 12 LDC’s from various bacterial strains. To a sample of pure LDC
(≈1 nmol in 60 µL), sodium cyanoborohydride (NaCNBH3, 1.0 mg, 16 µmol) was added
and was incubated at 0 °C for two minutes. The solution was centrifuged at 10,000 rpm
for 10 minutes. The solution was then placed on a 4 kDa Microcon filter and was washed
4 times with 300 µL 10 mM Potassium Phosphate buffer pH 6.0, containing 10 µM PLP.
After the final rinse, the solution was resuspended in 150 µL of the washing buffer, and
was incubated at 25 °C. After 18 hours, 10 µL of the solution was mixed with 7 µL of
loading buffer, was denatured at 80 °C for 7 minutes, and was loaded onto a 9%
acrylamide SDS-PAGE gel. Bands at approximately 80 kDa were excised and digested
and run on LC/MS, as described above.
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